Invivyd Reports Strong Q3 Growth and FDA Clearance

An announcement from Invivyd ( (IVVD) ) is now available.

On November 6, 2025, Invivyd reported its third-quarter financial results, highlighting a 41% year-over-year growth in PEMGARDA revenue and a strengthened cash position following a public offering. The company announced the FDA clearance for its VYD2311 clinical program, which includes pivotal trials expected to start by the end of 2025. Invivyd aims to secure its position as a leader in providing antibody protection against COVID-19 and is preparing for the potential commercial launch of VYD2311. Additionally, the company is exploring pipeline expansion beyond COVID-19, targeting other infectious diseases like RSV and measles.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.

To see Spark’s full report on IVVD stock, click here.

More about Invivyd

Invivyd, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibodies for the prevention of infectious diseases. Its primary products include PEMGARDA, an investigational monoclonal antibody, and VYD2311, a vaccine-alternative antibody aimed at preventing COVID-19. The company is committed to addressing unmet medical needs and expanding its pipeline beyond COVID-19 to include other pathogens.

Average Trading Volume: 7,676,642

Technical Sentiment Signal: Buy

Current Market Cap: $300.2M

Learn more about IVVD stock on TipRanks’ Stock Analysis page.